STX — Shield Therapeutics Share Price
Last trade - 00:00- £24.48m
- £36.35m
- £13.09m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 45.25 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -167.4% | ||
| Return on Equity | -261.66% | ||
| Operating Margin | -162.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.72 | 10.39 | 1.52 | 5.5 | 13.09 | 24.53 | 46.04 | 1.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anaemia. The Company operates through two segments: Feraccru (ferric maltol), and PT20. Its lead product Accrufer/Feraccru is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, United Kingdom, and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Directors
- Hans Hasler NEC (65)
- Gregory Madison CEO (53)
- Hans-Peter Rudolf CFO
- Jose Menoyo VPR
- Christian Schweiger NED
- Fabiana Lacerca-Allen NID (48)
- Peter Llewellyn-Davies NID
- Anders Lundstrom NID (59)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 3rd, 2015
- Public Since
- February 26th, 2016
- No. of Employees
- 73
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 1,041,690,484
- Address
- 3rd Fl, GATESHEAD, NE8 3D
- Web
- https://www.shieldtherapeutics.com/
- Phone
- +44 1915118500
- Auditors
- MAZARS LLP
Latest News for STX
Upcoming Events for STX
Full Year 2024 Shield Therapeutics PLC Earnings Release
Shield Therapeutics PLC Annual Shareholders Meeting
Half Year 2025 Shield Therapeutics PLC Earnings Release
Similar to STX
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 23:11 UTC, shares in Shield Therapeutics are trading at 2.35p. This share price information is delayed by 15 minutes.
Shares in Shield Therapeutics last closed at 2.35p and the price had moved by +58.78% over the past 365 days. In terms of relative price strength the Shield Therapeutics share price has outperformed the FTSE All Share Index by +52.55% over the past year.
The overall consensus recommendation for Shield Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreShield Therapeutics does not currently pay a dividend.
Shield Therapeutics does not currently pay a dividend.
Shield Therapeutics does not currently pay a dividend.
To buy shares in Shield Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 2.35p, shares in Shield Therapeutics had a market capitalisation of £24.48m.
Here are the trading details for Shield Therapeutics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: STX
Based on an overall assessment of its quality, value and momentum Shield Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Shield Therapeutics is 13.93p. That is 492.77% above the last closing price of 2.35p.
Analysts covering Shield Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -£0.03 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shield Therapeutics. Over the past six months, its share price has underperformed the FTSE All Share Index by -47.52%.
As of the last closing price of 2.35p, shares in Shield Therapeutics were trading -26.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shield Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 2.35p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shield Therapeutics' management team is headed by:
- Hans Hasler - NEC
- Gregory Madison - CEO
- Hans-Peter Rudolf - CFO
- Jose Menoyo - VPR
- Christian Schweiger - NED
- Fabiana Lacerca-Allen - NID
- Peter Llewellyn-Davies - NID
- Anders Lundstrom - NID